Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Oragenics Inc (OGEN)

Oragenics Inc (OGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,063
  • Shares Outstanding, K 4,481
  • Annual Sales, $ 40 K
  • Annual Income, $ -20,660 K
  • 60-Month Beta 0.31
  • Price/Sales 127.35
  • Price/Cash Flow N/A
  • Price/Book 1.99
Trade OGEN with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0150 +11.33%
on 04/17/24
1.4900 -24.16%
on 04/03/24
-0.2800 (-19.86%)
since 03/18/24
3-Month
1.0150 +11.33%
on 04/17/24
5.2687 -78.55%
on 01/23/24
-3.9200 (-77.62%)
since 01/18/24
52-Week
1.0150 +11.33%
on 04/17/24
7.7400 -85.40%
on 01/03/24
-2.1200 (-65.23%)
since 04/18/23

Most Recent Stories

More News
Oragenics to Participate in the World Vaccine Congress Washington

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces that Kim Murphy, Chief Executive...

OGEN : 1.1300 (+4.63%)
Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases, today reports favorable findings from third party laboratory...

OGEN : 1.1300 (+4.63%)
Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces the appointment of Janet Huffman...

OGEN : 1.1300 (+4.63%)
Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that the Company has entered...

OGEN : 1.1300 (+4.63%)
Oragenics, Inc. Regains Compliance with NYSE American

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that the Company has received...

OGEN : 1.1300 (+4.63%)
Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) , a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that its Board of Directors...

OGEN : 1.1300 (+4.63%)
Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotechnology company dedicated to fighting infectious diseases including COVID-19, today announced results indicating no...

OGEN : 1.1300 (+4.63%)
Oragenics, Inc. Receives NYSE American Notice

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that it received a Notice...

OGEN : 1.1300 (+4.63%)
Oragenics, Inc. Announces New Chair

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) , a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that on December 16, 2022...

OGEN : 1.1300 (+4.63%)
Oragenics to Participate in the 2022 BioFlorida Annual Conference

Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, announces its participation in the 2022 BioFlorida...

OGEN : 1.1300 (+4.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Oragenics Inc is a biotechnology company focused on the development and licensure of innovative products and technologies for improving human health.

See More

Key Turning Points

3rd Resistance Point 1.2067
2nd Resistance Point 1.1833
1st Resistance Point 1.1567
Last Price 1.1300
1st Support Level 1.1067
2nd Support Level 1.0833
3rd Support Level 1.0567

See More

52-Week High 7.7400
Fibonacci 61.8% 5.1710
Fibonacci 50% 4.3775
Fibonacci 38.2% 3.5839
Last Price 1.1300
52-Week Low 1.0150

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar